Collegium Pharmaceutical
As of the edition of 20 October 2026, Collegium Pharmaceutical runs 7 drugs, 6 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
- BioDelivery Sciences International: acquired in 2022; successor Collegium Pharmaceutical, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 1 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fentanyl | none listed | 6 |
| Buprenorphine | Ends 2028 (exclusivity) | 9 |
| Methylphenidate | none listed | 11 |
| Oxycodone | none listed | 2 |
| Tapentadol | Ends 2027 (exclusivity) | 4 |
| Naldemedine | Ends 2033 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Collegium Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Bones, joints and muscles: 1 trials led
- Chemically induced: 1 trials led
- Mental health: 1 trials led